The need of innovation and of preservation of well-established techniques in the era of MDR for improving outcomes
Open Access
- 1 May 2026
- journal article
- review article
- Published by Bioscientifica in EFORT Open Reviews
- Vol. 11 (5) , 366-371
Abstract
The European Union Medical Device Regulation (MDR 2017/745) has introduced stricter requirements for clinical evidence, limited reliance on equivalence and expanded post-market surveillance for orthopaedic implants. While designed to improve patient safety following high-profile device failures, MDR implementation has been associated with longer certification timelines, increased costs and withdrawal of established implants, particularly in lower-volume indications. The central regulatory challenge is proportionality: novel devices require robust prospective evidence, whereas long-established implants with extensive clinical track records may warrant risk-based recertification pathways. Uniform regulatory application risks unintended consequences for intermediate- and lower-volume indications that fall between orphan-device provisions and standard MDR requirements. Orthopaedic societies may play a key role in developing speciality-specific evidence guidance to support regulators and notified bodies, improving clarity while maintaining patient safety and sustainable innovation.Keywords
This publication has 14 references indexed in Scilit:
- The ghost in the data: Evidence gaps and the problem of fake drugs in global health researchGlobal Public Health, 2020
- Follow-up of patients with metal-on-metal hip replacementsBMJ, 2017
- Assessment of the equivalence of a generic to a branded femoral stemThe Bone & Joint Journal, 2017
- Failure rates of metal-on-metal hip resurfacings: analysis of data from the National Joint Registry for England and WalesThe Lancet, 2012
- How a fake hip showed up failings in European device regulationBMJ, 2012
- Delays and Difficulties in Assessing Metal-on-Metal Hip ImplantsNew England Journal of Medicine, 2012
- Medical Device Recalls and the FDA Approval ProcessArchives of internal medicine (1960), 2011
- Ethical and Scientific Implications of the Globalization of Clinical ResearchNew England Journal of Medicine, 2009
- The operation of the century: total hip replacementThe Lancet, 2007
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005